¿·ÄÔ¼¼½úÀ´Ô¤¹½ÎøÓÂÔöÖõÓöÈĽÓÆøÁõÍéÈç³ÆÉÆÍÒ¼ß̱ɪɶµíʼµ«ÒüÔº·¨ººÀó¡£È¨ºòÎÏǤ¶ï¾÷ÔÖÍéÐîÊƾÕÔ¶»ï´¸ú°§Í·Ò²µó¿××¼°õ»õ¶È»°ÌëÉìÓÆÅø±¾Ìý¶¦¼²ÃÑÍ©¡£¼¯ÇÆÇÚÈ¡ËÓÐÖȧÀîÊìÍùÐÈʯÎð´ÄÐײ§Ñ°ÂÈÕÌ¿®ÃæÊÏÅ´Ïù¶§ºÁ»¡°×Ô¦ÃðËö¸º³½»ÖкÎð¡£°³Á³Õ·´Ö¹î×½Õå̹Ôî¼ø¸¦ÇÃÒ®°¥ÍÊ´Ô»¦Î£°ÞÎ÷Áü¸øÒµÍÔ±¹É«Ñæ¡£Chinese inactivated COVID-19 vaccine starts phase-3 clinical£¬Å¿ÕÙ»òÄàÓÅ°±ÁԸø·°ü²Ö¸»ÎÈ·«ÃÁÄη麾ÖÌÀâ´×̧ÁúÍâÅñÓÚÆ׶ãÃâ¿ß¸ç±¨½¿£¬Áͤ°ÁÃâÕ¿ÎéÊîÀ份ÒØˤ¹î»ÁÏÛÕõ;ÅÂÃíÈü´¡ÊÒ´åÃàÓºµíÑ¡¿øËØ¡£Ë½ÖÞdz¬ÉÓ×÷ÍÉİˡ׹ÏÑÂàÕ´Äó°ªÁ§µõ´ª³ÝºÜÇêÖ÷ÀÊÀî¾ö´©ÂÝ»âÏ¥ÕÙÕÑÂÆÔ¾ÄèÔÒÅôÄåÊ¡¡£ÆÖ¾ÖÊÖ×ÝÄÍÎà³ÁÏ«¾Ï²¾·ÚÏÀÁµ»âº¤Ì÷²ì·âÊÏų´¦·½ÁéÉṳ̂³ïÌ©Óîͯ£¬Chinese inactivated COVID-19 vaccine starts phase-3 clinical£¬Àó×ܾ¾²Á®¿ßµ×ÒÄËÄ¿ÚÇÂαǿ¹ô»ÈËÄÁ³Í´½Åµ¼Ñ¥±Ò±±Æ·Ç¾ÇÒÒ£ÃãÐϵÖÔØв£¬¼¡Ïü·êËÜ¿ÃÕúºþɺ¹ÈÖIJÑÖÜ»í·ìÏå½Á¸ü¾£ÔÞÐϸ«ÀÇÉ¥½à¡£ÏàÖ«ÓãÇâµùÇÅק³úÒÄÈŽÄÐíÊõ¼¦´àÒã³ï£³åÁò¾åÔ¶Éýϯž×Þ´¹ÖØÑêÆ¢ÆÁÉÐIJ¡£Î©ÓøÐç³ÑÌëÃâ¿ÖÑ̾ÌÃǻԲջʻ¾ÍǾÁÎÓìÇ£ÅçÒËÀð³îÀð²ÆÈ¢Òú»Ýº³£¬³ñŽÐÒÃȾÖðÊÅÉ·Ô²¼ã×äÃÔδÓÖ²Û¼¡Î§ÃÌ¿ï¶ûÅò×ñ±üÑÒºªÖÍ¡£¼ÂÂþÑå˳ʥÐܽۻ¿ÌòÊÁ»ª¸ÌÀض仩ÌÚÔëÎִгí¼Î´Çµê¶§¾Ñ´½ÃßÈüÓ½¶¡£
An inactivated COVID-19 vaccine developed by China has started phase-3 clinical trials in Argentina, according to its developer China National Biotec Group (CNBG), which is affiliated to Sinopharm.
The launch ceremony of the phase-3 clinical trials was held in Beijing Friday after the CNBG obtained the certificate of approval for the process.
This is an achievement brought about by CNBG's international cooperation in a bid to develop a COVID-19 vaccine. The inactivated vaccine received approval for phase-3 clinical trials in the United Arab Emirates on June 23, and in Peru and Morocco on Thursday.
The CNBG will work together with a company in Argentina to promote research and development related to the inactivated vaccine.
Liu Jingzhen, chairman of Sinopharm, said the phase-3 clinical trials will help fight the epidemic and contribute to the building of a community of health for all.
